Low penetrance of a SDHB mutation in a large Dutch paraganglioma family
- PMID: 20540712
- PMCID: PMC2891715
- DOI: 10.1186/1471-2350-11-92
Low penetrance of a SDHB mutation in a large Dutch paraganglioma family
Abstract
Background: Germline mutations of the succinate dehydrogenase subunit B gene (SDHB) predispose carriers for paragangliomas, and current estimates of the chance of mutation carriers actually developing tumors (penetrance) are high. We evaluate the phenotype and penetrance of a germline SDHB mutation in a large and clinically well-characterized paraganglioma family.
Methods: Following identification of the mutation in a 31 year old index-patient, extensive clinical screening was performed in mutation carriers to evaluate the presence of head and neck, thoracic and abdominal paragangliomas. Presymptomatic DNA testing was performed in 19 family members.
Results: DNA analysis detected 14 further SDHB mutation carriers. Three mutation carriers (median age 78 years) declined clinical surveillance, but had no clinical signs or symptoms associated with paragangliomas. The remaining 11 mutation carriers (mean age 53, range 37-76 years) consented to clinical screening. In only two, aged 43 and 48 years, were subclinical vagal paragangliomas identified.
Conclusions: Only three of the fifteen mutation carriers in this family have developed paraganglioma, which results in a calculated penetrance of 26% at 48 years of age. This figure is lower than current estimates, and we conclude that the co-operation of this family allowed an almost complete attainment of mutation carriers, and the extensive clinical evaluation carried out allowed us to identify all affected individuals.
Figures


Similar articles
-
The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers.Clin Genet. 2018 Jan;93(1):60-66. doi: 10.1111/cge.13055. Epub 2017 Sep 6. Clin Genet. 2018. PMID: 28503760
-
The phenotype of SDHB germline mutation carriers: a nationwide study.Eur J Endocrinol. 2017 Aug;177(2):115-125. doi: 10.1530/EJE-17-0074. Epub 2017 May 10. Eur J Endocrinol. 2017. PMID: 28490599
-
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.JAMA. 2004 Aug 25;292(8):943-51. doi: 10.1001/jama.292.8.943. JAMA. 2004. PMID: 15328326
-
A novel germline (c.314T>A) SDHB variant in metastatic paraganglioma: case report and literature review.Front Endocrinol (Lausanne). 2025 Mar 27;16:1577421. doi: 10.3389/fendo.2025.1577421. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40213107 Free PMC article. Review.
-
Outcomes of SDHB Pathogenic Variant Carriers.J Clin Endocrinol Metab. 2024 Aug 13;109(9):2400-2410. doi: 10.1210/clinem/dgae233. J Clin Endocrinol Metab. 2024. PMID: 38605204 Free PMC article.
Cited by
-
European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137. doi: 10.1007/s00259-019-04398-1. Epub 2019 Jun 29. Eur J Nucl Med Mol Imaging. 2019. PMID: 31254038 Free PMC article.
-
Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.Nat Rev Endocrinol. 2024 Mar;20(3):168-184. doi: 10.1038/s41574-023-00926-0. Epub 2023 Dec 14. Nat Rev Endocrinol. 2024. PMID: 38097671 Review.
-
Phenotype of SDHB mutation carriers in the Netherlands.Fam Cancer. 2014 Dec;13(4):651-7. doi: 10.1007/s10689-014-9738-z. Fam Cancer. 2014. PMID: 25047027
-
High throughput proteomic and metabolic profiling identified target correction of metabolic abnormalities as a novel therapeutic approach in head and neck paraganglioma.Transl Oncol. 2021 Aug;14(8):101146. doi: 10.1016/j.tranon.2021.101146. Epub 2021 Jun 9. Transl Oncol. 2021. PMID: 34118692 Free PMC article.
-
Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.Clin Biochem Rev. 2017 Apr;38(2):69-100. Clin Biochem Rev. 2017. PMID: 29332973 Free PMC article. Review.
References
-
- Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943–951. doi: 10.1001/jama.292.8.943. - DOI - PubMed
-
- Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91:827–836. doi: 10.1210/jc.2005-1862. - DOI - PubMed
-
- Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91:4505–4509. doi: 10.1210/jc.2006-0423. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources